|
|
Profile
|
Delegates :
President&CEO Ryuji Yamamoto |
|
Incorporated :
December 20 , 2004 |
Paid in Capital :
10 Million yen |
Employees :
8 人 |
Address :
JS Ichigaya Bldg. 6F Chiyoda-ku, Gobancho, 5-1 TOKYO
〒102-0076
|
TEL/FAX :
+81-3-5530-8086 / +81-3-5530-8087 |
URL：
www.cytopathfinder.com/ |
Attachment :
|
Mission/Background :
CytoPathfinder, Inc. was established as a spin-off bio-venture of the National Institute of Advanced Industrial Science and Technology(AIST) vested with proprietary solid-phase transfection technologies in Dec. 2004.
In 2009, six years into its existence, what started as a drug discovery support company acquired Pharmacogenomics Innovative Solution Limited (PGXIS Ltd.),a UK based venture company specialized in pharmacogenomics with an eye on expanding its scope to include clinical development.
After 2011, we have improved solid transfection technology, and our activities has been focusing to supply transfection services to pharmaceutical companies and academia supporting their drug discoveries and medical studies. |
|
Technology & Business
|
CytoPathfinder offers products and services based on the solid-phase transfection technologies.
Various nucleic acids and transfection reagents are dried up as a non-covalently bound complex on the well surfaces of the microplate, transfection experiments can be easily done by simply seeding cells to the plate without exchanging medium culture. Solid transfection plates are ready for experiments at any time after long term of storage (12 months at -20℃ in freezer). Therefore it will be possible to treat sequentially one by one in case of large scale of screening of the microplates.
In addition, patented accelerator will improve transfection efficiency and stabilize transfection complexes, and therefore solid transfection can be applied for stem cells, primary cells, floating cells which are all hard to transfect. We can also supply high density microplate with1536 wells, that lead to comprehensive screening with even limited volume of rare cells.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Solid-phase Transfection Plates for siRNA/mRNA: ①Optimization plates ②Custom plates
|
Service/Marketing
|
One-step transfection: Just seed and watch! Enjoy efficient siRNA / miRNA transfections.
|
Effort to be known widely of solid transfection method. Come into wide use for the HTS such as the gene functional analysis.
|
Solid-phase Transfection Plates for plasmid DNA: ①Optimization plates ②Custom plates
|
Service/Marketing
|
One-step transfection: Just seed and watch! Enjoy efficient plasmid DNA transfections.
|
Come into wide use of this method. Development to improve DNA expression even for the differentiated cells.
|
Solid-phase Transfection Plates for Gene Editing using CRISPR-Cas9 system.
|
Service/Marketing
|
Products applied for gene editing using solid phase transfection method. High gene editing efficiency will be expected.
|
To gain high gene editing efficiency not only in producing variant Plasmid but in knock in knockout screening.
|
|
|
|
|
|
|
|
|
|
Highlights
|
1. Start to supply CRISPR-Cas9 solid plates.
2. Joint collaboration work with Phoenix Bio Co., Ltd. (Sales and marketing of "in vitro siRNA transfection assay kits" for human hepatocyte cells known as the product name "PXB-cells").
|
|
Hot news
|
We concluded the cooperative business agreement with Phoenix Bio Co., Ltd. on June 2019. According to this agreement, we started sales and marketing of "in vitro siRNA transfection assay kits" for PXB-cells. By using PXB-cells, drug metabolism, enzyme induction, enzyme inhibition evaluation of safety, transporter, drug efficacy to anti HBV can be done in vitro experiment. Combining with siRNA screening, investigation of mechanism - identification and interaction of target genes - would be expected.
|
|
Alliance strategy
|
Expand business globally with open innovation
1. Transfer our technologies to companies, universities, and research institutes.
2. Business collaboration with whom the synergy effect can be expected.
3. Expansion of the applicable cell species of the solid phase transfection technology by joint research.
4. Search the seeds of drug discovery by joint research.
5. Business deployment or OEM supply overseas with the support from companies with global sales network.
|
|
|